Human immunoglobulin procurement case
Current status of the Human immunoglobulin procurement case
Criminal prosecution arising from the procurement of substandard human immunoglobulin; a three-judge Trial-at-Bar was appointed and indictments were filed against Rambukwella and other accused.
What’s happened
Trial-at-Bar proceedings are active. He had previously spent months in remand before being released on bail.
- Court
- High Court Trial-at-Bar, Colombo
- Next hearing / due
- Next hearing not confirmed
- Alleged offence
- Conspiracy and criminal misappropriation of public funds through the purchase of substandard immunoglobulin vials
- Law / charge
- 13 counts: conspiracy, criminal misappropriation and aiding and abetting (per Sunday Times; not confirmed against the indictment)
- Amount involved
- About Rs. 144 million (some reports say Rs. 147 million); 6,195 vials reported
- Court
- Colombo High Court Trial-at-Bar (three judges, no jury)
- Accused
- Keheliya Rambukwella and 11 others, including ex-Health Secretary Janaka Chandragupta and supplier owner Sudath Janaka Fernando
- Investigating agency
- Criminal Investigation Department (CID); indictment filed by the Attorney General on 26 June 2025
What happened
In 2022, during Sri Lanka's economic crisis, the Health Ministry bought medicines under an Indian credit line. The Attorney General's case is that, around that period, officials changed procurement procedures and created an artificial shortage of drugs to justify buying stock (as reported by Ada Derana).
In October 2023 the National Medicines Regulatory Authority (NMRA) reported that a batch of human immunoglobulin vials, an antibody medicine, had failed quality tests and that forged documents had been used for Customs clearance. The Indian company named as the manufacturer reportedly told the NMRA it had not made or exported that batch.
The prosecution says the Medical Supplies Division of the Health Ministry received 6,195 vials of non-medicinal substances labelled as human immunoglobulin and Rituximab, and that more than Rs. 144 million of public money was misappropriated.
The charges
The indictment filed on 26 June 2025 contains 13 counts against 12 accused. Reports describe these as conspiracy, criminal misappropriation of state funds, and aiding and abetting. Sunday Times says the charges allege funds received under the Indian credit line were used to buy the substandard injections.
The accused include Keheliya Rambukwella, who was Health Minister at the time; former Health Ministry Secretary Janaka Chandragupta; the owner of the supplier company, Sudath Janaka Fernando; and several other health officials. Reports do not set out each accused person's individual role. These are charges, not findings; the accused are presumed innocent unless the court finds otherwise.
How it reached court
The CID began investigating after two complaints. Rambukwella was questioned several times, and on 2 February 2024 he was arrested and remanded, then later released on bail. He resigned as minister on 3 February 2024. According to Lanka Sara, the CID concluded its investigation after about one year and eight months.
In April 2025 the Attorney General asked the Chief Justice to appoint a Trial-at-Bar, a bench of three High Court judges sitting without a jury. Indictments were filed on 26 June 2025 and served in September 2025, when the defence argued bail applications and the Attorney General opposed bail.
In November 2025 a new bench was appointed after the original presiding judge retired and another was transferred. A pre-trial conference was fixed for 26 November 2025. One accused, Dr. Jayanath Buthpitiya, was reported to be overseas and subject to an arrest warrant.
Where it stands
The case is before the Trial-at-Bar and no verdict has been reported. The most recent available reporting is from November 2025 and concerns the pre-trial stage; no trial date or later hearing dates have been reported.
The prosecution has listed nearly 350 witnesses and about 300 documents and other productions. Rambukwella has publicly rejected wrongdoing in connection with the 2022 Indian credit line purchases, but no defence statement on the specific charges has been reported.
Separately, on 27 March 2026 the Supreme Court, in a civil fundamental-rights case about 2022 health-supplies purchases from a different supplier, found officials had breached the right to equality and ordered five respondents to pay Rs. 275 million in total, including Rs. 75 million from Rambukwella personally. That ruling does not concern the immunoglobulin charges.
No evidence has been reported as led at trial; the case is at the pre-trial stage. The items below are what the prosecution and regulators have publicly described, and the accused are presumed innocent.
Evidence is listed as it has been presented in proceedings or publicly reported, with the defence’s position where it has been made public. Evidence being presented is not a finding of guilt — only a court can make one.
- #1ForensicAlleged · not yet tested in court
6,195 vials alleged to be non-medicinal substances
Prosecution says
The prosecution says the Medical Supplies Division received 6,195 vials of non-medicinal substances labelled as human immunoglobulin and Rituximab. It puts the public funds misappropriated above Rs. 144 million.
Defence says
No public response on this point.
Sources (2)
- #2Official findingAlleged · not yet tested in court
NMRA report of failed quality tests and forged Customs documents
Prosecution says
In October 2023 the NMRA stated that a batch of immunoglobulin vials failed quality tests and that forged documents were submitted for Customs clearance. The Indian manufacturer named on the paperwork reportedly denied making or exporting the batch.
Defence says
Rambukwella's lawyer said in December 2023, before any arrest, that the original complaint was filed on Rambukwella's directions and that he had voluntarily given the CID documents and video material. This predates the indictment and is not a response to the charges.
Sources (2)
- #3CircumstantialAlleged · not yet tested in court
Alleged changes to procurement procedure and a false drug shortage
Prosecution says
As reported by Ada Derana, the prosecution's account is that in 2022 officials altered procurement procedures and created a false shortage of drugs to justify buying medicine stocks.
Defence says
In December 2022 Rambukwella publicly said no misappropriation occurred in the Indian credit line purchases, explaining that the credit line deadline and the time needed for tenders and quality checks drove the timetable. This was about the credit line purchases generally, not the indictment.
Sources (2)
- #4DocumentsExpected · not yet produced
Prosecution list of witnesses and productions
Prosecution says
The prosecution has listed nearly 350 witnesses, reportedly including former President Ranil Wickremesinghe, several former ministers and the NMRA chairman, and about 300 productions. The indictment names the individual documents it relies on.
Defence says
No public response on this point.
Court's view
At the November 2025 hearing the bench noted the prosecution had handed the defence a whole folder instead of the specific indicted document, and ordered it to separate and mark that document and give the defence a detailed note.
Sources (2)
Human immunoglobulin procurement case timeline
- 11 September 2024
Bail Granted
After about seven months in custody the Maligakanda Magistrate released him on two personal bonds of Rs. 5 million each and a Rs. 100,000 cash deposit, banned him from foreign travel and ordered him to hand over his passport.
Court: Maligakanda Magistrate's Court
Sources (2)
- 15 February 2024
Remanded
Keheliya Rambukwella and six others were further remanded until 29 February 2024 by the Maligakanda Magistrate's Court.
Court: Maligakanda Magistrate's Court
Sources (1)
- 3 February 2024
Remanded
The Maligakanda Magistrate's Court remanded Keheliya Rambukwella until 15 February 2024. The Deputy Solicitor General, for the Attorney General, said the allegation was conspiracy and aiding and abetting in supplying the immunoglobulin to the medical supply department.
Court: Maligakanda Magistrate's Court
Sources (1)
- 2 February 2024
Arrested
The CID arrested Keheliya Rambukwella after he came to its office to give a statement about the human immunoglobulin procurement, following questioning of about ten hours.
Court: High Court Trial-at-Bar, Colombo
Sources (1)

